Zoetis (ZTS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Zoetis (ZTS) do?
Zoetis Inc (ZTS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells prescription medicines, vaccines, parasiticides, and diagnostic tests for companion animals and livestock. Operates dedicated animal health research, manufacturing plants, and direct sales teams across dozens of countries. It is worth $32.83B on the market and sold $9.51B over the last year.
- Market cap
- $32.83B
- P/E ratio
- 13.7×
- Annual sales
- $9.51B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 13, 2026
Brands and businesses behind ZTS
- Apoquel: Daily oral prescription medication for allergic dog itch, generating revenue through veterinary clinic sales.
- Simparica Trio: Monthly chewable protecting dogs against heartworm, fleas, and ticks, sold via veterinary clinics and pet pharmacies.
- Librela: Monthly injectable monoclonal antibody for canine osteoarthritis pain, earning revenue from clinic administrations.
- Cytopoint: Injectable antibody therapy targeting canine skin allergies, earning recurring revenue through regular clinic visits.
- Solensia: Monthly injectable monoclonal antibody treating feline osteoarthritis pain, sold directly to veterinary practices.
- Revolution Plus: Topical parasiticide for cats preventing fleas, ticks, and worms, earning sales through veterinary prescriptions.
ZTS’s flags, in plain English
Each flag is a number from Zoetis’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Wide Gross Margin
Gross margin of 70.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earns Its Keep
Earns 57.1% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Fat Margins
Profit margin of 26.2%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Debt Is Driving
Heavy debt, 280% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about ZTS
How big is Zoetis?
Zoetis’ market cap is $32.83B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $9.51B: what customers paid the company over the last year, before any costs.
What is ZTS’s P/E ratio?
ZTS’s P/E ratio is 13.7×. Investors pay about 13.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ZTS?
Rival drug developers produce competing monoclonal antibodies and generic formulations that challenge key pet dermatology and osteoarthritis treatments. That is one risk on Zoetis’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Zoetis’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ZTS’s filings on SEC.gov. The Margin Monkey is research, not advice.
